Fewer drugs approved, more money spent - Where's the beef? By G. Steven Burrill Three years ago, when biotech was at its Wall Street heights, personalised medicine and its promise were on everyone's lips. Billions of dollars were being put to work to make targeted medicine a reality... and genomics… Read More
Recent advances in mass spectrometry for drug discovery and development By Dr Nelson Cooke Of the numerous types of analytical techniques used in drug discovery and development, mass spectrometry (MS) has become one of the most powerful tools for the analyses of a wide range of chemical and biological entities. Read More
DNA repair inhibition to treat cancer and other serious illnesses By Professor Stephen P. Jackson and Cheryl L. Bishop The stability of an organism's genome is essential for healthy functioning and survival. The information content and integrity of the genome are so important that a range of maintenance and repair… Read More
Urinary troubles for more than the ageing By Dr Anthony PDW Ford The needs of younger incontinence sufferers coupled with the ageing of the baby-boomer population portend a big boost in demand for effective and well tolerated new medicines for lower urinary-tract dysfunction. This market is under-served today, presenting a… Read More
By Dr Steven Bodovitz and Dr Scott D. Patterson The potential for parallel protein-based analyses to define a new era in diagnostics and drug development is generating considerable excitement in the field of proteomics. However, the discovery of differentially expressed proteins that correlate with a disease state or a drug… Read More
Biotechnology-based Orphan Drugs - Achievements and challenges By Dr Erik Tambuyzer For many patients suffering from rare diseases, there are simply no medicines available to treat their condition. With an estimated 20-30 million such patients in Europe alone, rare diseases collectively represent a significant unmet medical need. Individual disease groups,… Read More
The cost and value of three-dimensional protein structure By Professor Raymond C. Stevens During the past few years we have seen the cost of protein three-dimensional structure determination begin to converge by protein family type, there has been a commoditisation of high-throughput structure based drug discovery technology components, and the… Read More
Molecular pathology and the art of drug design By Dr Keith McCullagh The current explosion of interest in sophisticated genomic technologies, computerised robotics and high throughput screening of diverse molecular libraries appears to have been associated with a reduction in research productivity in recent years, as judged by the rate… Read More
Public Relations and the Drug Discovery Industry By Dr Richard Franklin The use of the Public Relations (PR) industry to promote all facets of the pharmaceutical industry is on the increase. We take a brief look at the various uses of PR and the sectors that are being promoted. Public… Read More
The Protein Biochip Content Problem By Dr Steven Bodovitz The protein biochip industry has a content problem that is not only slowing its development as a whole but possibly the development of the entire proteomics industry. In science, for a problem to have its own name, it needs to be… Read More
New developments in antigen-specific immunotherapies By Dr Jorg Schneider and Professor Andrew J. McMichael Novel therapeutic vaccines offer hope in the fight against chronic infectious disease and cancer. Vaccination has been used effectively for more than 200 years to protect individuals from a range of infectious diseases such as polio… Read More
Functional proteomics in drug discovery By Dr Stefan W. Henning and Dr Leodevico L. Ilag The critical bottleneck of the drug discovery process is developing the right drug for the right target. Today proteins represent more than 90% of druggable targets and will most likely remain the single most important… Read More
In Silico Structure-based Drug Design - Shifting the bottleneck? By Dr Jonathan Heal Drug Discovery The use of in silico methods in drug design has grown significantly in popularity over the past couple of years. Indeed many pharma companies have already adopted some type of virtual screening capability to complement… Read More
Surface Plasmon Resonance's impact on drug discovery - resolution, throughput and versatility By Dr David G. Myszka and Dr Rebecca L. Rich Surface plasmon resonance (SPR) biosensors have rapidly become a standard tool within the pharmaceutical and biotechnology industries. Label-free, real-time measurements are the calling card for this technology, which… Read More
The role of ZEBRAFISH in drug discovery By Dr Paul Goldsmith and Roberto Solari The NIH has ranked the Zebrafish as the third most important experimental organism after man, the Sanger Centre is sequencing the genome and many medical researchers are shifting over to it. But will the zebrafish have… Read More
TRANSCRIPTOMICS - Realising the promise with a new era of drug discovery and diagnostics By Dr Bruce Seligmann The advent of modern genomics has provided new ways to link targets to diseases and validate these targets. The result is the potential for a new era of drug discovery transcriptomics or… Read More